Companies / United Arab Emirates
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Investment To Improve Integration, Therapeutic Focus
December 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
The UAE's largest drugmaker, Gulf Pharmaceutical Industries (Julphar) has revealed an AED1.23bn (US$1.23bn) investment plan for 2008-2011 to expand domestic and international manufacturing, increase the focus on non-communicable diseases and improve the company's vertical integration. BMI considers the announcement a response to uncertain macroeconomic conditions, a changing domestic disease profile and a squeeze on the company's traditional strengths from low cost generics at one end of the spectrum and top-end patented drugs at the